Vaccine Therapiesfind mydrugscancerWhen Will Melanoma Vaccines Be Proven Effective?Cancer Vaccines: Between the Idea and the RealityImmunotherapy: past, present and futureCurrent Developments in Cancer Vaccines and Cellular ImmunotherapyAdjuvant autologous renal tumour cell vaccine and the risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trialAdjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group (SWOG-9035)Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing AdenocarcinomaPhase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory moleculeInduction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA VirusAmplification of Virus-Induced Antimelanoma T-Cell Reactivity by High-Dose Interferon- a2b: Implications for Cancer Vaccines
Adjuvant autologous renal tumour cell vaccine and the risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group (SWOG-9035)
Pilot Study of a Dual Gene Recombinant Avipox Vaccine Containing Both Carcinoembryonic Antigen (CEA) and B7.1 Transgenes in Patients with Recurrent CEA-expressing Adenocarcinoma
Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
Induction of Protective Host Immunity to Carcinoembryonic Antigen (CEA), a Self-Antigen in CEA Transgenic Mice, by Immunizing with a Recombinant Vaccinia-CEA Virus
Amplification of Virus-Induced Antimelanoma T-Cell Reactivity by High-Dose Interferon- a2b: Implications for Cancer Vaccines